A case is reported of a 54-year-old female patient with schizophrenia and cognitive impairment. Her memory dysfunction improved following the addition of donepezil to quetiapine. The possible implications for future studies are reviewed.
Court J A, Piggott M A, Lloyd S, Cookson N, Ballard C G, McKeith IG et al. (2000) Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease and in relation to neuroleptic medications. Neuroscience98: 79–87
2.
Cuesta M J, Peralta V, Zarzuela A (1998) Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res33: 141–150
3.
de Vries P J, Honer W G, Kemp P M, McKenna P J (2001) Dementia as a complication of schizophrenia. J Neurol Neurosurg Psychiatry70: 588–596
4.
Friedman J I, Temporini H, Davis K L (1999) Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry45: 1–16
5.
Friedman J I, Adler D N, Howanitz E, Temporini H, Harvey P D, Davis K L (2001) Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia. Schizophr Res49: 228-228
6.
George T P, Vessicchio J C, Sahady D M, Head C A, Tamine A, Bregartner T A et al. (2001) Effects of smoking abstinence on cognitive function in schizophrenia. Biol Psychiatry49: 5S-5S
7.
Green M F (1996) What are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry153: 321–330
8.
Greenberg S M, Tennis M K, Brown L B, Gomez-Isla T, Hayden D L, Schoenfeld D A et al. (2000) Donepezil therapy in clinical practice. Arch Neurol57: 94–99
9.
Greene Y M, Tariot P N, Wishart H, Cox C, Holt C J, Schwid S, Noviasky J (2000) A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol20: 350–356
10.
Harvey P D, Parrella M, White L, Mohs R C, Davidson M, Davis K L (1999) Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res35: 77–84
11.
Heinrichs R W, Zakzanis K K (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychologica12: 426–445
12.
Holt D J, Herman M M, Hyde T M, Kleinman J E, Sinton C M, German D C et al. (1999) Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience94: 21–31
13.
Levin E D, Wilson W, Rose J E, McEvoy J (1996) Nicotine– haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology15: 429–436
14.
Meltzer H Y, McGurk S R (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull25: 233–255
15.
Mihailescu S, Drucker-Colin R (2000) Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res31: 131–144
16.
Powchik P, Davidson M, Haroutunian V, Gabriel S M, Purohit D P, Perl D P et al. (1998) Postmortem studies in schizophrenia. Schizophr Bull24: 325–341
17.
Risch S C, McGurk S, Horner M D, Nahas Z, Owens S D, Molloy M et al. (2001) A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase7: 105–110
18.
Rogers S L, Farlow M R, Doody R S, Mohs R, Friedhoff L T (1998) A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology50: 136–145
19.
Sarter M (1994) Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?Psychopharmacology114: 539–550
20.
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Vehara T et al.(2001) The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry49: 861–868
21.
Tandon R, Greden J (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. Am J Psychiatry46: 745–753
